Andrew J. Murphy

2021

In 2021, Andrew J. Murphy earned a total compensation of $7.1M as Executive Vice President, Research at Regeneron Pharmaceuticals, a 35% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$819,410
Option Awards$3,347,323
Salary$724,500
Stock Awards$2,231,397
Other$24,200
Total$7,146,830

Murphy received $3.3M in option awards, accounting for 47% of the total pay in 2021.

Murphy also received $819.4K in non-equity incentive plan, $724.5K in salary, $2.2M in stock awards and $24.2K in other compensation.

Rankings

In 2021, Andrew J. Murphy's compensation ranked 1,696th out of 12,397 executives tracked by ExecPay. In other words, Murphy earned more than 86.3% of executives.

ClassificationRankingPercentile
All
1,696
out of 12,397
86th
Division
Manufacturing
624
out of 5,492
89th
Major group
Chemicals And Allied Products
229
out of 2,367
90th
Industry group
Drugs
192
out of 2,090
91st
Industry
Pharmaceutical Preparations
129
out of 1,537
92nd
Source: SEC filing on April 21, 2022.

Murphy's colleagues

We found five more compensation records of executives who worked with Andrew J. Murphy at Regeneron Pharmaceuticals in 2021.

2021

Daniel Van Plew

Regeneron Pharmaceuticals

Executive Vice President and General Manager, Industrial Operations and Product Supply

2021

Robert Landry

Regeneron Pharmaceuticals

Chief Financial Officer

2021

Joseph LaRosa

Regeneron Pharmaceuticals

General Counsel

2021

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer

2021

George Yancopoulos

Regeneron Pharmaceuticals

Chief Scientific Officer

News

You may also like